In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals (EIGR), with a price target of $28. The company’s shares closed on Friday at $10.19.
Higgins commented:
“We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs.”
According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -13.4% and a 26.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.
Eiger Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28, a 174.8% upside from current levels. In a report released today, Wedbush also maintained a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
Based on Eiger Biopharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.53 million. In comparison, last year the company had a GAAP net loss of $9.92 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.
